The authors aimed to determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients achieved a similar disease-free survival (DFS) with any of these regimens.

READ FULL ARTICLE Curated publisher From Mdlinx